The Latest

• 

  Deep Dive

  Biotech M&A is accelerating. Track the deals that are happening here.

  GSK on Wednesday agreed to pay $950 million to acquire startup 35Bio, which is developing a treatment for different types of pulmonary hypertension.

  Updated 8 hours ago

  Deals

• 

  Sponsored by ProBio CDMO

  Small and mighty: single-domain antibodies pack a biological punch

  VHH antibodies: they’re not just small, they're modular engineering platforms, capable of powerful biological activity. But with great power comes great challenges!

  Pharma

• 

  Obesity drugs

  Novo, searching for a spark, spotlights new data for three-pronged obesity drug

  Novo’s answer to a closely watched Lilly drug spurred roughly 20% weight loss after 24 weeks in a Phase 2 trial, results one of its executives claimed to be “differentiating.”

  Clinical Trials

• 

  Startup launches

  Slate starts up with $130M and a headache drug from China

  The biotech is developing a drug aimed at a protein called PACAP, which has emerged as a potentially new way to prevent the onset of migraines.

  Biotech

• 

  Gene editing

  FDA fleshes out new roadmap for testing personalized therapies

  At an event on Monday, the agency officially unveiled long-awaited draft guidance meant to help speed the development of bespoke treatments for extremely rare diseases.

  FDA

• 

  Merck to split cancer, specialty drug businesses in leadership shakeup

  Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.

  Pharma

• 

  Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy

  The acquisition bolsters Gilead’s sputtering cell therapy business with a medication the company expects to become a “foundational treatment” for the blood cancer, its CEO said.

  Deals

• 

  Vir climbs on Astellas deal, study results for ‘masked’ T cell engager

  According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an infectious disease specialist before changing course.

  Biotech

• 

  Novo to cut GLP-1 drug prices; Palvella soars on study data

  Wegovy and Ozempic’s list prices will be reduced by as much as 50% effective next year. Elsewhere, Palvella’s market value surged past $1 billion while Pfizer nabbed rights to another obesity drug.

  Biotech

• 

  FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals

  In a NEJM article, Commissioner Martin Makary and top deputy Vinay Prasad argued that the new policy should lower development costs and speed development without compromising agency standards.

  FDA

• 

  Obesity drugs

  Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study

  Shares fell by more than 15% on results showing study participants receiving Novo’s CagriSema lost less weight than those who took Lilly’s Zepbound.

  Pharma

• 

  Deep Dive // IPO window

  Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

  Generate Biomedicines outlined terms for an offering that, at its midpoint, could be worth $400 million — the most since Acelyrin’s $540 million stock issuance in May 2023.

  Updated Feb. 23, 2026

  Biotech

• 

  Trump sets fresh 10% global tariff — and plans to increase further

  The new duties will go into effect Feb. 24, although the president has since signaled he will raise the rate to 15%.

  Updated Feb. 21, 2026

  Pharma

• 

  AI is slashing jobs across industries. Will pharma be next?

  Despite a wave of AI-fueled layoffs, the pharma and biotech industries could be spared from massive cutbacks for now.

  Pharma

• 

  Roche gets FDA decision date on closely watched breast cancer drug

  The agency could by late December approve a therapy that Roche sees as potentially becoming a new treatment standard for certain breast tumors. 

  Pharma

• 

  News roundup

  Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi

  Madrigal shares fell 11% despite again topping consensus sales numbers. Elsewhere, Daiichi Sankyo named a new research chief and J&J halted recruitment in an Alzheimer’s trial. 

  Biotech

• 

  Grail’s multi-cancer early detection test misses study goal

  Shares in the company lost about half their value in Friday trading after use of the test wasn’t associated with a statistically significant reduction in late-stage cancer diagnoses.

  Clinical Trials

• 

  Emerging biotech

  Altesa, run by former Trump official, raises $75M for well-traveled lung drug

  Led by Brett Giroir and GSK’s ex-chief medical officer, Altesa is advancing a medicine that’s changed hands multiple times and once failed a study in asthma.  

  Updated Feb. 20, 2026

  Biotech

• 

  Vaccines

  FDA reverses course on Moderna’s flu vaccine

  In response to a query from BioPharma Dive, an HHS spokesperson said the FDA will “maintain its high standards during drug review and potential licensure stages.”

  Updated Feb. 19, 2026

  Biotech

• 

  Psychedelics stocks rise as Compass’ psilocybin drug heads to FDA

  Shares of at least four other developers were up by mid-single digits to low-double digits at certain points on Tuesday.

  Biotech

• 

  Deep Dive // Emerging biotech

  Biotech startups are built on venture capital. Track funding rounds here.

  RA Capital has been the most active investor so far this year among the firms tracked by BioPharma Dive year, participating in 6 funding rounds all with at least $103 million in total proceeds.

  Updated Feb. 20, 2026

  Biotech

• 

  Brain drug revival

  An Alzheimer’s startup emerges with $175M in venture backing

  Backed by Wellington, Sanofi Ventures and a division of J.P. Morgan, Korsana Therapeutics is studying a treatment originally developed by hub-and-spoke biotech Paragon Therapeutics.

  Biotech

• 

  Compass, with Phase 3 hits, ready to take psilocybin to the FDA

  The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S. market.

  Biotech

• 

  Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6

  The Australian company will retain rights for an end-stage kidney disease indication currently being tested in a Phase 3 trial while Lilly explores other uses.

  Pharma

• 

  FDA accepts BMS protein degrader for review; Disc rare disease drug rejected

  Cytokinetics’ heart disease drug secured European approval. Elsewhere, Teva and Sanofi reported longer-term data from an experimental therapy targeting ulcerative colitis and Crohn’s disease.

  Pharma

• 

  Ocular claims a win with eye drug data even as shares sink

  Investors were looking for a greater difference between Ocular’s experimental medicine and a low-dose version of Eylea, analysts said.

  Biotech

More stories